- Drug delivery platform developer Lexaria Bioscience recently received its 20th patent — granted in Japan for beverages with lipophilic active agents
- The active agents include non-psychoactive cannabinoids and over-the-counter NSAIDS such as ibuprofen and aspirin that target pain and inflammation
- Lexaria’s DehydraTECH platform transforms drugs into a powder or liquid form that maintains the drug’s efficacy and allows it to be assimilated by the body more rapidly than normal oral ingestion of pills
- The company will also announce the latest results from six key R&D projects focusing on concentration levels, tolerability and avoidance of incidental new molecular entities (“NMEs”) soon
Drug assimilation technology innovator Lexaria Bioscience (NASDAQ: LEXX) is demonstrating the versatility of its DehydraTECH platform with the announcement of a patent for “stable ready-to-drink beverage compositions comprising lipophilic active agents” — the company’s first granted in Japan.
“This new patent adds to our existing suite of granted patents spanning the EU, the U.S., India and Australia, and continues to build value for Lexaria shareholders and clients,” CEO Chris Bunka stated…
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW? Ask our Editor
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is part of the InvestorBrandNetwork.
